Cervical cancer screening by high risk HPV testing in routine practice: Results at one year recall of high risk HPV-positive and cytology-negative women

Journal of Medical Screening

Volumn 21, Issue 1, 2014, Pages 30-37

  Del Mistro, Annarosa ^a   Frayle, Helena ^a   Ferro, Antonio ^b   Callegaro, Susanna ^c   Del Sole, Annamaria ^d,i   Stomeo, Anna ^e   Cirillo, Emanuela ^f,i   Fedato, Chiara ^g   Pagni, Silvana ^h   Barzon, Luisa ^h   Zorzi, Manuel ^g   Baracco, Susanna ^g   Cogo, Carla ^g   Rizzi, Martina ^a   Baboci, Lorena ^a   Masiero, Sara ^h   Palù, Giorgio ^h   Bertazzo, Alessandra ^b,i   Farruggio, Angelo ^b   Cocco, Patrizia ^b,i   Tumaini, Paolo Lucio ^b   Gerace, Pierfrancesco ^b,i   Ortu, Fausta ^c   Borgato, Loretta ^c   Maso, Renata ^c,i   Bo, Patrizio ^c   Peron, Fiorenza ^c,i   Spitti, Remigia ^d   Astolfi, Elena ^d,i   Di Mambro, Enrico ^d   Saliani, Nicola Paolo ^d,i   Gallo, Lorenza ^e,i   Borghi, Laura ^e,i   Buoso, Rita ^e,i   Simoncello, Ivana ^f   Onnis, GianLibero ^f,i   Nardelli, Giovanni ^f   Minucci, Daria ^f   Insacco, Egle ^f   Matteucci, Mario ^f   Braggion, Gabriella ^d,f   more..

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Local Health Unit 17 Este Monselice   (Italy)

^c Department of Prevention Local Health Unit 15 Alta padovana   (Italy)

^d Local Health Unit 19 Adria   (Italy)

^e Local Health Unit AUSL 18 19   (Italy)

^f Sports Medicine Unit   (Italy)

^g Occupational Health Unit   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ Istituto Oncologico Veneto IRCCS ^*  (Italy)

Author keywords

Follow up; HPV; Organized screening; Triage

Indexed keywords

ADULT; ARTICLE; COLPOSCOPY; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; FOLLOW-UP; HUMAN; ISOLATION AND PURIFICATION; ITALY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGANIZED SCREENING; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; WART VIRUS;

FOLLOW-UP; HPV; ORGANIZED SCREENING; TRIAGE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84901334835     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141314522219     Document Type: Article

References (34)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses (2005b). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 90. Lyon, IARC.
2. Bulkmans N, Rozendaal L, Snijders P, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
3. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
4. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-74.
5. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
6. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papilllomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
7. Naucler P, Ryd W, Tornberg S, et al. Human papilloma-virus and Papanicolau tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as a primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
9. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
10. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-82.
11. Leinonen M, Nieminen P, Kotaniemi Talonen L, et al. Age specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomised setting. J Natl Cancer Inst 2009;101:1612-32.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
13. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, published online November 3, 2013.
14. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
15. Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. J Med Screen 2010;17:79-86.
16. Zorzi M, Del Mistro A, Farruggio A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG 2013;120:1260-7.
17. Coleman D, Day N, Douglas G, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer 1993;29A(Suppl 4): S1-S38.
18. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol 2010;21:448-58.
19. Gruppo Italiano Screening Citologico (GISCi). Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. Belluno: Evidenzia, 2010.19p (Italian). http://www.gisci.it/documenti/documenti_gisci/documento_hpv.pdf. Accessed 22 march 2013.
20. Ronco G, Accetta G, Angeloni C, et al. Health Technology Assessment. Ricerca del DNA di Papillomavirus Umano (HPV) come test primario per lo screening dei precursori del cancro del collo dell'utero. HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev 2012;36(3): S1.
21. Herbert A, Bergeron C, Wiener H, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:213-9.
22. Rebolj M, Lynge E. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer 2010;103:310-4.
23. Rebolj M, Pribac I, Frederijsen ME, Lynge E. The problem of false-positive Human Papillomavirus DNA tests in cervical screening. Curr Pharmac Des 2013;19:1439-49.
24. Elkins CT, de Vries CE, Stephens J, Suarez AA. Hybrid Capture 2 test results after an initial equivocal RLU/CO value are dependent on age. Am J Pathol 2013;139:605-10.
25. Kotaniemi-Talonen L, Malila N, Nieminen P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008;123:2902-6.
26. Mesher D, Szarewski A, Cadman L, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102:1405-10.
27. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2011;11:1160-71.
28. Gillio-Tos A, De Marco L, Carozzi FM, et al. Clinical impact of the analytical specificity of Hybrid Capture 2: data from the NTCC study. J Clin Microbiol 2013;51:2901-7.
29. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24.
30. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3{thorn} and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013;17(5 Suppl 1): S56-63.
31. Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/07E. ISBN 978-90-5549-866-6. Available at: http://www.gezondheidsraad.nl/en/publications/prevention/results/taxonomy%3A189 accessed 2013.
32. Goldsmith MR, Bankhead CR, Kehoe ST, Marsh G, Austoker J. Information and cervical screening: a qualitative study of women's awareness, understanding and information needs about HPV. J Med Screen 2007;14:29-33.
33. Carozzi F, Gillio Tos A, Confortini M, et al. Risk of high grade CIN on follow up in HPV positive women according to baseline p16-INK4A results: prospective analysis of a sub-study nested in a randomized controlled trial. Lancet Oncol 2013;14:168-76.
34. Kuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30S:F107-F116.